[ English | Bahasa Malaysia ] Hari ini ialah 26 Feb 2024, 09:52 AM (Terakhir dikemaskini pada: 22nd Feb 2024)

Text Red Text Black Text Blue Text Green Text Smaller Text Reset Text Larger

Publication Details
Year :


Journal :

Hue Tran Hornig-Do, Arianna Montanari, Agata Rozanska, Helen A Tuppen, Abdulraheem A Almalki, Dyg P Abg-Kamaludin, Laura Frontali, Silvia Francisci, Robert N Lightowlers and Zofia M Chrzanowska-Lightowlers (2014). Human mitochondrial leucyl tRNA synthase can suppress non cognate pathogenic mt-tRNA mutations. EMBO Molecular Medicine 6(2): 183-193

Abstract :

Disorders of the mitochondrial genome cause a wide spectrum of disease, these present mainly as neurological and/or muscle related pathologies. Due to the intractability of the human mitochondrial genome there are currently no effective treatments for these disorders. The majority of the pathogenic mutations lie in the genes encoding mitochondrial tRNAs. Consequently, the biochemical deficiency is due to mitochondrial protein synthesis defects, which manifest as aberrant cellular respiration and ATP synthesis. It has previously been reported that overexpression of mitochondrial aminoacyl tRNA synthetases has been effective, in cell lines, at partially suppressing the defects resulting from mutations in their cognate mt-tRNAs. We now show that leucyl tRNA synthetase is able to partially rescue defects caused by mutations in non-cognate mt-tRNAs. Further, a C terminal peptide alone can enter mitochondria and interact with the same spectrum of mt-tRNAs as the entire synthetase, in intact cells. These data support the possibility that a small peptide could correct at least the biochemical defect associated with many mt-tRNA mutations, inferring a novel therapy for these disorders.




Laman ini sesuai dilihat menggunakan Firefox (24.0) dengan resolusi 1280 x 768 pixels atau lebih.

Lokasi Kami


Kami terletak di Jalan Pahang, 50588 Kuala Lumpur, Malaysia. Klik pada imej peta untuk melancarkan servis Google Maps.

Hubungi Kami